Active monitoring and reporting system for drug-induced diseases

Abstract

The invention relates to an active monitoring and reporting system for drug-induced diseases, which is used for monitoring clinical treatment process information of a patient, performing graded early warning on adverse drug events and drug use errors, performing active reporting, outputting graded early warning according to the risk degree after drug use risk information is monitored, and meanwhile, performing graded early warning according to the treatment process information of the patient. According to the method and the system, the adverse drug events are actively reported after the relevance between the adverse reactions and the suspicious drugs is determined, so that the drug use risk is effectively prevented, and the reporting rate and the reporting accuracy of the adverse events are improved.

Description

technical field [0001] The invention relates to the field of medical technology, in particular to an active monitoring and reporting system for drug-induced diseases. Background technique [0002] Adverse drug events (ADEs) and medication errors (ME) are one of the main causes of drug-induced diseases. Important measures of institutional adverse event rates. The current main ADE monitoring methods include adverse event medical record review method and voluntary reporting system method. The occurrence of ADE is collected through medical record review and voluntary reporting. The number and quality of reports and signal detection capabilities of this method depend on medical institutions. Reporting awareness and cooperation, there are problems such as false positives, missed negatives, and post-event reporting, which cannot reflect the true occurrence level of ADE or ME, and the current ADE monitoring is "post-event" passive monitoring, lacking in advance prevention. [0003...

AI Technical Summary

Problems solved by technology

[0004] 1. The current ADE / ME monitoring system has problems such as false positives, missed negatives, low reporting rate, low reporting accuracy, and inconsistent evaluation standards for the correlation between suspicious drugs and adverse events, so it cannot reflect the true occurrence level of ADE or ME. This further resulted in the small sample size, low sample quality and poor timeliness of the raw data of adverse drug event research, which brought inconvenience to clinical drug safety supervision and drug quality feedback

[0005] 2. Some ADE / ME can be avoided or discovered at an early stage, but the current ADE / ME monitoring system is mostly for post-event treatment and lacks an early warning mechanism. The lack of early warning makes clinical treatment miss the best time to intervene in ADE, increasing the Incidence and severity of ADEs

[0006] 3. ADE reporting requires accuracy and needs a certain amount of time to be evidence-based, while ADE early warning requires timeliness and early warning of potential ADE risks. The current ADE / ME monitoring system is difficult to simultaneously meet the requirements of accurate reporting and timely early warning

Images